Testosterone and mortality

Czech version

Authors: Luboslav Stárka
Authors‘ workplace: Endokrinologický ústav, Praha
Published in: Vnitř Lék 2016; 62(Suppl 3): 127-130
Category: Reviews

Overview

Subnormal levels of testosterone are frequently found in men of higher age category. Hypogonadal men have lower life expectancy than men with full androgenization and cardiovascular disease, obesity or diabetes is often associated with hypotestosteronemia. Low testosterone level is risk factor for these diseases. However, until now it is not clear whether testosterone deficiency is a cause or consequence of atherosclerosis or metabolic syndrome. A handful of symptoms and metabolic risk markers in hypogonadal men can be ameliorated by testosterone supplementation. Testosterone treatment increased sexual activity and well-being and had a moderate benefit with respect to depressive symptoms but no significant benefit to vitality. Testosterone has a beneficial effect on cardiovascular risk factors, but there is not clear whether it reduces mortality.

Key words:
civilization diseases – late onset hypogonadism – morbidity – mortality – testosterone – testosterone supplementation

Sources

1. Araujo AB, Dixon JM, Suarez EA et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96(10): 3007–3019. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–1137>.

2. Bronson FH, Matherne CM. Exposure to anabolic-androgenic steroids shortens life span of male mice. Med Sci Sports Exerc 1997; 29(5): 615–619.

3. Comhaire F. Hormone replacement therapy and longevity. Andrologia 2016; 48(1): 65–68. Dostupné z DOI: <http://dx.doi.org/10.1111/and.12419>.

4. Corona G, Rastrelli G, Monami M et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165(5): 687–701. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11–0447>.

5. Doleček R, Burejsa B, Hampl R et al. Hladiny některých hormonálních látek v séru (plazmě) ve stáří. I. Čas Lék Čes 1983; 122(27): 850–856.

6. Drori D, Folman Y. Environmental effects on longevity in the male rate: exercise, mating, castration and restricted feeding. Exp Gerontol 1976; 11(1–2): 25–32.

7. Eisenberg ML, Li S, Herder D et al. Testosterone therapy and mortality risk. Int J Impot Res 2015; 27(2): 46–48. Dostupné z DOI: <http://dx.doi.org/10.1038/ijir.2014.29>.

8. Ellison PT, Bribiescas RG, Bentley GR et al. Population variation in age-related decline in male salivary testosterone. Hum Reprod 2002; 17(12): 3251–3253.

9. Friedrich N, Schneider HJ, Haring R et al. Improved prediction of all-cause mortality by a combination of serum total testosterone and insulin-like growth factor I in adult men. Steroids 2012; 77(1–2): 52–58. Dostupné z DOI: <http://dx.doi.org/10.1016/j.steroids.2011.10.005>.

10. Hwang K, Miner M. Controversies in testosterone replacement therapy: testosterone and cardiovascular disease. Asian J Androl 2015; 17(2): 187–191. Dostupné z DOI: <http://dx.doi.org/10.4103/1008–682X.146968>.

11. Hyde Z, Norman PE, Flicker L et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab 2012; 97(1): 179–189. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–1617>.

12. Laughlin GA, Barret-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93(1): 68–75.

13. Mazur A. Biosocial models of deviant behavior among male army veterans. Biol Psycol 1995; 41(3): 271–293.

14. Min KJ, Lee CK, Park HN. The lifespan of Korean eunuchs. Curr Bio 2012; 22(18): R792-R793. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cub.2012.06.036>.

15. Morgentaler A, Zitzmann M, Traish AM et al. International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic. Aging Male 2015; 18(4): 205–206. Dostupné z DOI: <http://dx.doi.org/10.3109/13685538.2015.1106469>.

16. Muraleedharan V, Marsh H, Kapoor D et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013; 169(6): 725–733. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-13–0321>.

17. Nieschlag E, Kramer U, Nieschlag S. Androgens shorten the longevity of women: sopranos last longer. Exp Clin Endocrinol Diabetes 2003; 111(4): 230–231.

18. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. Nature 1993; 366(6452): 215.

19. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab 2013; 98(11): 4300–4310. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–1970>.

20. Sartorius G, Spasevska S, Idan A et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf) 2012; 77(5): 755–763. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2012.04432.x>.

21. Sharma R, Oni OA, Gupta K et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 2015; 36(40): 2706–2715. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv346>.

22. Shores MM, Matsumoto AM. Testosterone, aging and survival: biomarker or deficiency. Curr Opin Endocrinol Diabetes Obes 2014; 21(3): 209–216. Dostupné z DOI: <http://dx.doi.org/10.1097/MED.0000000000000057>.

23. Shores MM, Matsumoto AM, Sloan KL et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166(15): 1660–1665.

24. Shores MM, Smith NL, Forsberg CW et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97(6): 2050–2058. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–2591>.

25. Shores MM, Arnold AM, Biggs ML et al. Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. Clin Endocrinol (Oxf) 2014; 81(5): 746–753. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12452>.

26. Snyder PJ, Bhasin S, Cunningham GR et al. Effects of testosterone treatment in older men. N Engl J Med 2016; 374(7): 611–624. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1506119>.

27. Stárka L. Mužský hypogonadismus a civilizační onemocnění. Čas Lék Čes 2012; 151(2): 69–72. Dostupné z WWW: http://www.prolekare.cz/casopis-lekaru-ceskych-clanek/muzsky-hypogonadismus-a-civilizacni-nemocneni-37351.

28. Tanna MS, Schwartzbard A, Berger JS et al. The role of tesosterone therapy in cardiovascular mortality: culprit or innocent bystander? Curr Atheroscler Rep 2015; 17(3): 490. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–015–0490–0>.

29. Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94(7): 2482–2488. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008–2650>.

30. ÚZIS. Zdravotnická ročenka České republiky 2014: 26. Dostupné z WWW: http://www.uzis.cz/katalog/rocenky/zdravotnicka-rocenka-ceske-republiky.

31. Vigen R, O‘Donnell CI, Barón AE et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310(17): 1829–1836. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.280386>. Erratum in JAMA. 2014; 311(9): 967.